Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian Cooperative Study

Journal of Clinical Oncology

Volumn 19, Issue 22, 2001, Pages 4209-4215

  Boccardo, F ^a   Rubagotti, A ^a   Amoroso, D ^a   Mesiti, M ^a   Romeo, D ^a   Caroti, C ^a   Farris, A ^a   Cruciani, G ^a   Villa, E ^a   Schieppati, G ^a   Mustacchi, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ITALY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SURVIVAL RATE; TREATMENT FAILURE; VISCERA;

EID: 0035890568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.22.4209     Document Type: Article

References (27)

1. The control of breast cancer: The role of tamoxifen
2. Adjuvant tamoxifen in early breast cancer: An overview of the randomised trials
3. Iatrogenic risk of endometrial carcinoma after treatment for breast cancer in a large French case-control study
4. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
5. Use of tamoxifen for breast cancer
6. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
7. Aminoglutethimide in the treatment of metastatic breast carcinoma
8. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer
9. Low-dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer
10. Reporting results of cancer treatment
11. Nonparametric estimation from incomplete observations
12. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: I. Introduction and design
13. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II. Analysis and examples
14. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
15. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen
16. Coronary heart disease mortality and adjuvant tamoxifen therapy
17. Occurrence of stroke with tamoxifen in NSABP B-24
18. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
19. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
20. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer
21. Tamoxifen versus aminoglutethimide versus tamoxifen combined with aminoglutethimide in the treatment of advanced breast carcinoma
22. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen
23. Anastrozole vs. tamoxifen in hormone-dependent advanced breast cancer: A phase II randomized trial
24. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
25. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
26. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial - The Exemestane Study Group
27. Use of aromatase inhibitors in the adjuvant treatment of breast cancer